Retatrutide (LY3437943) is a next-generation 39-amino acid synthetic peptide engineered as a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — a mechanistic advancement beyond dual agonists like tirzepatide. By engaging all three incretin and counter-regulatory hormone pathways in a single molecule, retatrutide has demonstrated superior metabolic outcomes in preclinical and Phase 2 clinical research, including up to 24.2% mean body weight reduction at 48 weeks in obesity models.
Its GIP receptor activity enhances insulin secretion and lipid clearance, GLP-1 agonism drives appetite suppression and delayed gastric emptying, while glucagon receptor engagement promotes hepatic fat oxidation, thermogenesis, and direct anti-fibrotic signaling in liver tissue — making it one of the most studied compounds in current metabolic and MASH research.
Specifications:
- Purity: ≥99% (HPLC verified)
- Form: Lyophilized powder
- Storage: −20°C
For Research Use Only.
Marcus T. –
Exceptional quality and fast shipping. Received my order within 3 days and the COA confirmed 99.4% purity — exactly as advertised. Will be ordering again.